Side-by-side comparison of AI visibility scores, market position, and capabilities
Senior living and long-term care management software for skilled nursing, assisted living, and home health organizations. Minneapolis, MN. Acquired by ResMed.
MatrixCare is a Minneapolis, Minnesota-based provider of electronic health record and business management software for the senior living and post-acute care market. Acquired by ResMed (NYSE: RMD) in 2018, MatrixCare operates as ResMed's long-term care software division and serves over 15,000 care settings across skilled nursing facilities, senior living communities, home health agencies, and hospice providers. The platform provides EHR, billing, scheduling, and analytics capabilities designed for the clinical and operational complexity of long-term care.\n\nMatrixCare's product suite includes separate but integrated modules for skilled nursing, senior living (assisted living and memory care), home health, and hospice care, reflecting the different clinical workflows and regulatory requirements across these settings. The skilled nursing module addresses Medicare and Medicaid billing complexity, MDS documentation, and therapy management. The senior living module focuses on activity of daily living documentation, resident assessment tracking, and billing for private-pay and Medicaid waiver programs.\n\nResMed's acquisition of MatrixCare reflected the strategic importance of care coordination between home-based care (ResMed's core sleep therapy and respiratory device business) and facility-based post-acute care. The combined organization can offer integrated monitoring data from connected medical devices alongside clinical documentation in the EHR, positioning MatrixCare within ResMed's broader digital health strategy. MatrixCare competes directly with PointClickCare as the two dominant EHR platforms in the North American LTPAC market.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.